

Galecto Biotech ApS

Ole Maaløes Vej 3, 2200 Copenhagen N

CVR no. 34 87 83 66

**Annual report for the period
1 January to 31 December 2020**

Adopted at the annual general meeting on 4 June
2021

Steen Rode
chairman

Table of contents

	Page
Statements	
Statement by management on the annual report	1
Independent auditor's report	2
 Management's review	
Company details	5
Management's review	6
 Financial statements	
Income statement 1 January - 31 December	7
Balance sheet 31 December	8
Statement of changes in equity	10
Notes to the annual report	11
Accounting policies	13

Statement by management on the annual report

The supervisory and executive boards have today discussed and approved the annual report of Galecto Biotech ApS for the financial year 1 January - 31 December 2020.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2020 and of the results of the company's operations for the financial year 1 January - 31 December 2020.

In our opinion, management's review includes a fair review of the matters dealt with in the management's review.

Management recommends that the annual report should be approved by the company in general meeting.

Copenhagen, 4 June 2021

Executive board

Hans Schambye

Supervisory board

Hans Schambye

Jon Freve

Independent auditor's report

To the shareholder of Galecto Biotech ApS

Opinion

We have audited the financial statements of Galecto Biotech ApS for the financial year 1 January - 31 December 2020, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared under the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2020 and of the results of the company's operations for the financial year 1 January - 31 December 2020 in accordance with the Danish Financial Statements Act.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

Independence

We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements, that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Independent auditor's report

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independent auditor's report

Statement on management's review

Management is responsible for management's review.

Our opinion on the financial statements does not cover management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.

Copenhagen, 4 June 2021

EY

Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28

Christian S. Johansen
statsautoriseret revisor
MNE no. 33234

Company details

The company	<p>Galecto Biotech ApS Ole Maaløes Vej 3 2200 Copenhagen N</p> <p>CVR no.: 34 87 83 66</p> <p>Reporting period: 1 January - 31 December 2020</p> <p>Incorporated: 3 December 2012</p> <p>Domicile: Copenhagen</p>
Primary activity	<p>The Company's object is to operate in research and experimental development within biotechnology, as well as related activities.</p>
Supervisory board	<p>Hans Schambye Jon Freve</p>
Executive board	<p>Hans Schambye</p>
Auditors	<p>EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36 2000 Frederiksberg</p>

Management's review

Business review

The Company's object is to operate in research and experimental development within biotechnology, as well as related activities.

Financial review

The company's income statement for the year ended 31 December 2020 shows a profit of EUR 213.718, and the balance sheet at 31 December 2020 shows equity of EUR 2.904.076.

Significant events occurring after the end of the financial year

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

Income statement 1 January - 31 December

	Note	2020 EUR	2019 EUR
Gross profit		4.883.512	2.423.114
Staff costs	1	-4.402.507	-2.053.641
Profit/loss before net financials		481.005	369.473
Financial income	2	833.894	762.147
Financial costs	3	-1.040.902	-714.074
Profit/loss before tax		273.997	417.546
Tax on profit/loss for the year	4	-60.279	-93.669
Profit/loss for the year		213.718	323.877
Recommended appropriation of profit/loss			
Retained earnings		213.718	323.877
		213.718	323.877

Balance sheet 31 December

	Note	2020 EUR	2019 EUR
Assets			
Deposits		243.942	7.609
Fixed asset investments		243.942	7.609
Total non-current assets		243.942	7.609
Receivables from group enterprises		857.740	0
Other receivables		224.618	611.499
Corporation tax		1.478.226	736.067
Prepayments		125.899	0
Receivables		2.686.483	1.347.566
Cash at bank and in hand		2.536.814	2.729.793
Total current assets		5.223.297	4.077.359
Total assets		5.467.239	4.084.968

Balance sheet 31 December

	Note	2020 EUR	2019 EUR
Equity and liabilities			
Share capital		10.704	10.706
Retained earnings		2.893.372	2.679.654
Equity		2.904.076	2.690.360
Payable to group enterprises		750.070	776.130
Total non-current liabilities		750.070	776.130
Other credit institutions		464	41.968
Trade payables		1.039.382	499.612
Other payables		773.247	76.898
Total current liabilities		1.813.093	618.478
Total liabilities		2.563.163	1.394.608
Total equity and liabilities		5.467.239	4.084.968
Rent and lease liabilities	5		
Contingent liabilities	6		
Mortgages and collateral	7		
Related parties and ownership structure	8		

Statement of changes in equity

	Share capital	Retained earnings	Total
	EUR	EUR	EUR
Equity at 1 January 2020	10.706	2.679.654	2.690.360
Exchange adjustments	-2	0	-2
Net profit/loss for the year	0	213.718	213.718
Equity at 31 December 2020	10.704	2.893.372	2.904.076

Notes

	2020 EUR	2019 EUR
1 Staff costs		
Wages and salaries	3.788.144	2.049.999
Other social security costs	4.828	3.642
Other staff costs	609.535	0
	4.402.507	2.053.641
Average number of employees	16	11
2 Financial income		
Interest received from group enterprises	823.920	657.701
Other financial income	9.974	104.446
	833.894	762.147
3 Financial costs		
Financial expenses, group enterprises	904.800	690.005
Other financial costs	136.102	24.069
	1.040.902	714.074
4 Tax on profit/loss for the year		
Joint taxation contribution	60.279	93.669
	60.279	93.669

Notes

	2020 EUR	2019 EUR
5 Rent and lease liabilities		
Operating lease liabilities.		
Total future lease payments:		
Liabilities under rental or lease agreements until maturity in total	656.980	194.760
	656.980	194.760

6 Contingent liabilities

The company is jointly taxed with its parent company, Galecto Biotech AB (administrative company for the joint taxation), and jointly and severally liable with other jointly taxed entities for payment of income taxes as well as for payment of withholding taxes on dividends, interest and royalties.

7 Mortgages and collateral

The company has deposited EUR 168 thousand on a collateral account. This amount is to serve as security for the payable amount of EUR 0.5 thousand in favour of credit institutions.

8 Related parties and ownership structure

Galecto Biotech AB
Ole Maaløes Vej 3
2200 Copenhagen N

Galecto Biotech AB owns a 100% interest in Galecto Biotech ApS.

Galecto Biotech ApS is included in the Consolidated Financial Statement of Galecto, Inc.
The Consolidated Financial Statements can be obtained on the following addresses: Galecto, Inc., Ole Maaløes Vej 3, 2200 København N.

Accounting policies

The annual report of Galecto Biotech ApS for 2020 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, as well as provisions applying to reporting class C entities.

The accounting policies applied are consistent with those of last year.

The annual report for 2020 is presented in EUR.

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Income statement

Gross profit/loss

In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue.

Gross profit reflects an aggregation of revenue and other operating income less costs of other external expenses.

Revenue

Revenue comprising income from research and development provided by Galecto Biotech ApS to related parties, is recognised as the services are provided.

Accounting policies

Revenue is net of all types of discounts granted.

Directs costs

Directs costs include the direct attributable costs used in generating the year's revenue.

Other external costs

Other external costs include expenses related to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Other external costs also comprise research and development costs that do not qualify for capitalisation.

Galecto capitalizes costs related to purchase of equipment above EUR 10,000 per individual piece of equipment.

Staff costs

Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees. The item is net of refunds made by public authorities. Staff costs also includes shared based compensation that is issued by Galecto, Inc. Shared based compensation is measured at estimated fair value and is included as compensation expense over the vesting period during which service is provided in exchange for the award.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial year. Net financials include interest income and expenses, realised and unrealised capital/exchange gains and losses on securities and foreign currency transactions.

Tax on profit/loss for the year

Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, including changes arising from changes in tax rates, is recognised in the income statement as regards the portion that relates to entries directly in equity.

As a practice, the Danish tax authorities have chosen to pay the Group's corporation tax receivable to Galecto Biotech ApS. For this reason, the Group's tax receivable under the Danish R&D tax credit scheme is recognized in the annual report of Galecto Biotech ApS.

Receivables

Receivables are measured at amortised cost.

Accounting policies

Income tax and deferred tax

Deferred tax assets, including the tax base of tax losses allowed for carry forward, are measured at the value to which the asset is expected to be realised, either as a set-off against tax on future income or as a set-off against deferred tax liabilities within the same legal tax entity. Any deferred net tax assets are measured at net realisable value.

Liabilities

Liabilities are measured at amortised cost, which is usually equivalent to nominal value.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses. If foreign currency instruments are considered cash flow hedges, any unrealised value adjustments are taken directly to a fair value reserve under 'Equity'.